A process is described for removing halogen compounds, particularly chlorine compounds, from a process fluid, comprising the steps of (i) passing a process fluid containing hydrogen halide over a first sorbent to remove hydrogen halide and generate a hydrogen halide depleted process fluid and then, (ii) passing the hydrogen halide depleted process fluid over a second different sorbent to remove organic halide compounds therefrom. A purification system suitable for removing hydrogen halide and organic halide compounds from process fluids is also described.

Provided is a hybrid process for producing high-purity para-xylene from a feedstock of aromatic hydrocarbon isomer fractions having 8 carbon atoms, in a liquid phase. The process includes a liquid chromatography separation step and a crystallization step of the para-xylene from the purified stream of para-xylene obtained at the separation step.

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

Methods for transferring a carbon dioxide based separation procedure from a first chromatographic system to a second one involve identifying an average column pressure for the separation in the first system is identified, determining a measured average column pressure for the separation in the second system, and comparing the measured average column pressure with the identified average column pressures. To more closely match the identified average column pressure, the methods involve: (a) altering a cross-sectional area of a column packed with media in the second system; and/or (b) adding makeup fluid along the length of the column in the second system. Columns with the characteristics used in the methods and second chromatographic systems are disclosed.

Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido Asn.sup.A21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

The invention provides for methods and processes for producing, isolating, and purifying modified proteins. In particular, the invention provides for the production, isolation and purification of PEGylated recombinant methionyl human granulocyte colony stimulating factor used for therapeutic purposes.

The present invention relates to the use of redox agents for purification of the CRM 197 variant of diphtheria toxin. The invention further relates to multi-step purification of CRM 197 from bacterial fermentates.

In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, said method comprising: a) subjecting the mixture to a first chromatography matrix, wherein the protein of interest binds to the first chromatography matrix; b) contacting the first chromatography matrix with a first wash solution which has a pH of at least 9.0, and does not comprise arginine or an arginine derivative; and c) eluting the protein of interest from the first chromatography matrix into an elution solution.

Methods of preparing steviol glycosides, including Rebaudioside D, Rebaudioside E, Rebaudioside M, Rebaudioside N and Rebaudioside O are provided herein. Sweetener and sweetened consumables containing Rebaudioside D, Rebaudioside E, Rebaudioside M, Rebaudioside N and Rebaudioside O are also provided herein.

The present disclosure relates to nucleic acid extraction and purification methods and devices to accomplish the same.